High Dose Selection for General Toxicity Studies of New Medicines
https://doi.org/10.30895/2312-7821-2023-11-2-145-154
Abstract
High dose selection is a key methodological element in general toxicity studies of medicines. It determines the informative value of study results, the compliance with the principles of ethical and rational use of experimental animals, and the accuracy of predicting the safety of new medicines for human use. The literature data and the regulatory experience in evaluating preclinical study results suggest that the selection of an inappropriate high dose is a very common error in planning toxicity studies. This error leads to a significant or complete loss of the informative value of study results; the results become useless for assessing the safety of new medicinal products for human use.
The aim of this study was to analyse the current regulatory requirements for high dose selection for general toxicity studies of medicines.
The analysis suggests that unreasonably high doses may be selected for toxicity studies because methodological recommendations are prone to interpretation errors. Their potential for ambiguity stems from the absence of specific standardised upper limits for toxic doses or sufficiently clear dose selection criteria. Prerequisites for properly planning preclinical safety studies of new medicines include compliance with dose selection requirements of regulatory toxicology and implementation of a clinically and toxicologically sound decision-making algorithm.
Funding: The study reported in this publication was carried out as part of publicly funded research project № 056-00052-23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. 121021800098-4).
About the Authors
G. N. Engalycheva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Galina N. Engalycheva, Cand. Sci. (Biol.)
8/2 Petrovsky Blvd, Moscow 127051
R. D. Subaev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Rashid D. Subaev, Dr. Sci. (Med.)
8/2 Petrovsky Blvd, Moscow 127051
References
1. Sewell F, Corvaro M, Andrus A, Burke J, Daston G, Delaney B, et al. Recommendations on dose level selection for repeat dose toxicity studies. Arch Toxicol. 2022;96:1921–34. https://doi.org/10.1007/s00204-022-03293-3
2. Buckley LA, Dorato MA. High dose selection in general toxicity studies for drug development: a pharmaceutical industry perspective. Regul Toxicol Pharmacol. 2009;54(3):301–7. https://doi.org/10.1016/j.yrtph.2009.05.015
3. Shekunova EV, Kovaleva MA, Makarova MN, Makarov VG. Dose selection in preclinical studies: cross-species dose conversion. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020;10(1):19–28 (In Russ.). https://doi.org/10.30895/1991-2919-2020-10-1-19-28
4. Woutersen M, Muller A, Pronk MEJ, Cnubben NHP, Hakkert BC. Regulating human safety: how dose selection in toxicity studies impacts human health hazard assessment and subsequent risk management options. Regul Toxicol Pharmacol. 2020;114:104660. https://doi.org/10.1016/j.yrtph.2020.104660
5. Kociba RJ. Issues in biochemical applications to risk assessment: how should the MTD be selected for chronic bioassays? Environ Health Perspect. 1987;76:169–74. https://doi.org/10.1289/ehp.8776169
6. Saunders MD. A review of the main considerations for formulation development in preclinical toxicology studies. Int J Toxicol. 2021;40(6):551–6. https://doi.org/10.1177/10915818211043756
Supplementary files
Review
For citations:
Engalycheva G.N., Subaev R.D. High Dose Selection for General Toxicity Studies of New Medicines. Safety and Risk of Pharmacotherapy. 2023;11(2):145-154. (In Russ.) https://doi.org/10.30895/2312-7821-2023-11-2-145-154
Views:
1019
Email this article 